Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats

American Journal of Transplantation

Volumn 5, Issue 8, 2005, Pages 1856-1867

  Chung, Byung Ha ^a   Li, Can ^a,b   Sun, Bo Kyung ^a   Lim, Sun Woo ^a   Ahn, Kyung Ohk ^a   Yang, Ji Hun ^a   Choi, Yoon Hee ^a   Yoon, Kun Ho ^a   Sugawara, Akira ^c   Ito, Sadayoshi ^c   Kim, Jin ^a   Yang, Chul Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b YANBIAN UNIVERSITY MEDICAL COLLEGE   (China)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclosporine; Diabetes mellitus; Nephrotoxicity; Rosiglitazone

Indexed keywords

CALCINEURIN INHIBITOR; CASPASE 3; COMPLEMENTARY DNA; CYCLOSPORIN A; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; INSULIN; MESSENGER RNA; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; RAT;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; CYCLOSPORINE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS; KIDNEY; OSTEOPONTIN; PANCREATIC DISEASES; RATS; RATS, SPRAGUE-DAWLEY; SIALOGLYCOPROTEINS; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 22844440738     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00979.x     Document Type: Article

References (60)

1. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-1100.
2. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine- associated chronic nephropathy. N Engl J Med 1984; 311: 699-705.
3. Campistol JM, Sacks SH. Mechanisms of nephrotoxicity. Transplantation 2000; 69: S5-S10.
4. Pichler RH, Franceschini N, Young BA et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186-1196.
5. Shihab FS, Andoh TF, Tanner AM et al. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 1141-1151.
6. Justo P, Lorz C, Sanz A, Egido J, Ortiz A. Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. J Am Soc Nephrol 2003; 14: 3072-3080.
7. Yang CW, Faulkner GR, Wahba IM et al. Expression of apoptosis-related genes in chronic cyclosporine nephrotoxicity in mice. Am J Transplant 2002; 2: 391-319.
8. Thomas SE, Andoh TF, Pichler RH et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998; 53: 897-908.
9. Shihab FS, Andoh TF, Tanner AM, Yi H, Bennett WM. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999; 56: 2147-2159.
10. First MR, Gerber DA, Hariharan S, Kaufman DB, Shapiro R. Post-transplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002; 73: 379-386.
11. Hjelmesaeth J, Hartmann A, Kofstad J et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979-983.
12. Ishizuka J, Gugliuzza KK, Wassmuth Z et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation 1993; 56: 1486-1490.
13. Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396-402.
14. Jindal RM, Hjelmesaeth J. Impact and management of post-transplant diabetes mellitus. Transplantation 2000; 70(11 Suppl.): SS58-SS63.
15. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002; 62: 1440-1446.
16. Cheng-Lai A, Levine A. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Dis 2000; 2: 326-333.
17. Raskin P, Rappaport EB, Cole ST, Van Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278-284.
18. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A for the Rosiglitazone Clinical Trials Study Group. Once-and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-315.
19. Barroso I, Gurnell M, Crowley VE et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
20. Buckingham RE, Al-Barazanji KA, Toseland CD et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326-1334.
21. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14-30.
22. Yue TI TL, Chen J, Bao W et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001; 104: 2588-2594.
23. Wayman NS, Hattori Y, McDonald MC et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002; 16: 1027-1040.
24. Desouza CV, Murthy SN, Diez J et al. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J Cardiovasc Pharmacol Ther 2003; 8: 297-305.
25. Chakrabarti R, Misra P, Vikramadithyan RK et al. Antidiabetic and hypolipidemic potential of DRF 2519-a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol 2004; 491: 195-206.
26. Trivedi M, Marwaha A, Lokhandwala M. Rosiglitazone restores G-protein coupling, recruitment, and function of renal dopamine D1A receptor in obese Zucker rats. Hypertension 2004; 43: 376-382.
27. Yang CW, Ahn HJ, Kim WY et al. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation 2003; 75: 309-315.
28. Li C, Yang CW, Kim WY et al. Reversibility of chronic cyclosporine nephropathy in rats after withdrawal of cyclosporine. Am J Physiol Renal Physiol 2003; 284: F389-F398.
29. Lim SW, Li C, Sun BK et al. Long-term treatment with cyclosporine decreases aquaporins and urea transporters in the rat kidney. Am J Physiol Renal Physiol 2004; 287: F139-F151.
30. Li C, Yang CW, Park CW et al. Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats. Kidney Int 2003; 63: 454-463.
31. Basadonna G, Montorsi F, Dakizaki K, Merrell RC. Cyclosporine A and islet function. Am J Surg 1988; 156: 191-193.
32. Bani Sacchi T, Bani D, Filipponi F, Mickel A, Houssin D. Immunocytochemical and ultra structural changes of islet cells in rats treated long-term with cyclosporine at immunotherapeutic doses. Transplantation 1990; 49: 982-987.
33. Nam JH, Mun JI, Kim SI et al. beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001; 71: 1417-1423.
34. Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396-402.
35. Buckingham RE, Al-Barazanji KA, Toseland CD et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326-1334.
36. Finegood DT, McArthur MD, Kojwang D et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
37. Ishida H, Takizawa M, Ozawa S et al. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. Metabolism 2004; 53: 488-494.
38. Guyton K, Bond R, Reilly C, Gilkeson G, Halushka P, Cook J. Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation. J Leukoc Biol 2001; 69: 631-638.
39. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
40. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004; 53: 200-208.
41. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910.
42. Sun BK, Li C, Lim SW et al. Expression of transforming growth factor-beta-inducible gene-h3 in normal and cyclosporine-treated rat kidney. J Lab Clin Med 2004; 143: 175-183.
43. Young BA, Burdmann EA, Johnson RJ et al. Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int 1995; 48: 431-438.
44. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol 2004; 286: H742-H748.
45. Tao L, Liu HR, Gao E et al. Antioxidative, antinitrative, and vasculo-protective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003; 108: 2805-2811.
46. de Dios ST, Bruemmer D, Dilley RJ et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003; 107: 2548-2550.
47. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-934.
48. Sivarajah A, Chatterjee PK, Patel NS et al. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 2003; 23: 267-276.
49. Yue TL, Bao W, Jucker BM et al. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 2003; 108: 2393-2399.
50. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005; 130: 685-696.
51. Liu HR, Tao L, Gao E et al. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 2004; 62: 135-144.
52. Justo P, Lorz C, Sanz A, Egido J, Ortiz A. Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. J Am Soc Nephrol 2003; 14: 3072-3080.
53. Burdmann EA, Andoh TF, Nast CC et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491-F499.
54. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodelling. Am J Physiol Heart Circ Physiol 2005; 288: H1037-H1043.
55. Sugawara A, Takeuchi K, Uruno A, Kudo M, Sato K, Ito S. Effects of mitogen-activated protein kinase pathway and co-activator CREP-binding protein on peroxisome proliferator-activated receptor-gamma-mediated transcription suppression of angiotensin II type 1 receptor gene. Hypertens Res 2003; 26: 623-628.
56. Burgess SJ, Singer GG, Brennan DC. Effect of troglitazone on cyclosporine whole blood levels. Transplantation 1998; 66: 272.
57. Kaplan B, Friedman G, Jacobs M et al. Potential interaction of troglitazone and cyclosporine. Transplantation 1998; 65: 1399-1400.
58. Baldwin D Jr, Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 2004; 77: 1009-1014.
59. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 2002; 51: 1110-1117.
60. Umrani DN, Banday AA, Hussain T, Lokhandwala MF. Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats. Hypertension 2002; 40: 880-885.